Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment
Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL
Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.
Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies
Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.
Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL
Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512